SCHEDULE 13G/A: Vanguard Group Discloses 7.26% Passive Stake in USANA Health Sciences

The Vanguard Group has filed an updated Schedule 13G, reporting a 7.26% beneficial ownership stake in USANA Health Sciences Inc. as of March 31, 2025.

Summary

• The Vanguard Group reported beneficial ownership of 1,373,908 shares of USANA Health Sciences Inc. common stock.
• This represents 7.26% of the total outstanding shares of USANA Health Sciences Inc.
• The filing indicates that Vanguard holds 0 shares with sole voting power, 35,758 shares with shared voting power, 1,326,693 shares with sole dispositive power, and 47,215 shares with shared dispositive power.
• This filing is an Amendment No. 6 to a previous Schedule 13G, updating their reported holdings.
• The Vanguard Group certified that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 5

Explanation: The document is a routine Schedule 13G filing, which is a passive ownership disclosure and does not inherently convey positive or negative sentiment regarding the issuer's performance or prospects.

Positives

• The Vanguard Group, a major institutional investor, holds a significant 7.26% stake in USANA Health Sciences Inc., which can be viewed as a sign of institutional confidence and stability in the company's stock.

Negatives

• No specific negative information regarding USANA Health Sciences Inc.'s operations or financial performance is disclosed in this beneficial ownership report.

Risks

• This filing, a Schedule 13G, primarily reports beneficial ownership and does not detail specific risks related to USANA Health Sciences Inc.'s operations or financial performance.

Future Outlook

This Schedule 13G filing does not contain any forward-looking statements or guidance regarding USANA Health Sciences Inc.'s future outlook.

Management Comments

• The Vanguard Group certified that the securities were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities.

Industry Context

This filing is a routine disclosure of beneficial ownership by a large institutional investor and does not provide specific industry context or trends for the health sciences sector.

Comparison to Industry Standards

• This beneficial ownership report does not provide information suitable for comparison to industry-specific financial or operational standards or specific comparable companies or projects.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional holder's stake, potentially offering a sense of stability.
• Management: Awareness of a large, passive institutional investor on the shareholder register.

Next Steps

• The Vanguard Group will file an amendment to this Schedule 13G if there are material changes to their beneficial ownership or intent, as required by SEC regulations.

Key Dates

Keywords

USANA Health Sciences, Vanguard Group, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, SEC Filing